Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-414 ocular side effect management study in EGFR-amplified glioblastoma
NL-OMON48749Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of depatuxizumab mafodotin in glioblastoma (GBM) and Gliosarcoma (GS) (3 arms), sponsored by AbbVie Inc. Planned start Apr 2018; status: withdrawn.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NL-OMON48749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48749.